Company Profiles

driven by the PitchBook Platform

Numerate

Numerate
2007 FOUNDED
PRIVATE STATUS
11-50 EMPLOYEES
Grant LATEST DEAL TYPE
$17.5M TOTAL AMOUNT RAISED
6 INVESTORS
Description

Developer of a drug engineering platform designed to transform small molecule drug discovery. The company's drug design platform combines advances in computer science and statistics with traditional medicinal chemistry approaches to overcome major challenges in small molecule drug discovery and significantly accelerate candidate selection and optimization, transforming the discovery of new medicines that fill significant therapeutic gaps by harnessing the vast computational power of the cloud and the ever-increasing amounts of drug discovery data by applying proprietary artificial intelligence algorithms.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
1150 Bayhill Drive
Suite 203
San Bruno, CA 94066
United States

+1 (650) 472-0632
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Numerate’s full profile, request a free trial.

Numerate Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 15-Nov-2017 $17.5M Completed Generating Revenue
4. Later Stage VC (Series A) 04-Jun-2014 00.000 000.00 000.00 Completed Generating Revenue
3. Early Stage VC (Series B) 20-Mar-2009 00.000 00.00 0000 Completed Startup
2. Early Stage VC (Series A3) 17-Nov-2008 $2.5M $3.73M $13.5M Completed Startup
1. Early Stage VC (Series A2) 20-May-2008 $1.24M $1.24M $6.97M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Numerate Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00 00 00 00 00.000
To view this company’s complete Cap Table request access »

Numerate Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Atlas Venture Venture Capital Minority 000 0000 000000 0
Foundation Capital Venture Capital Minority 000 0000 000000 0
Lanza Tech Ventures Venture Capital Minority 000 0000 000000 0
Leader Ventures Lender/Debt Provider Minority 000 0000 000000 0
Lilly Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Numerate Executive Team (8)

Name Title Board
Seat
Contact
Info
Guido Lanza President, Chief Executive Officer & Board Member
John Griffin Ph.D Chief Scientific Officer
Brandon Allgood Ph.D Chief Technology Officer & Co-Founder
E. Lacey Gordon Controller
Brian Raimundo Director, Medicinal Chemistry
You’re viewing 5 of 8 executives. Get the full list »

Numerate Board Members (5)

Name Representing Role Since Contact
Info
Guido Lanza Numerate President, Chief Executive Officer & Board Member 000 0000
Lucio Lanza Ph.D Numerate Advisor & Board Member 000 0000
Steven Hall Ph.D Lilly Ventures Board Member 000 0000

2 Former Board Members

You’re viewing 3 of 5 board members. Get the full list »